Phase 1 N=32 PF-04634817 Renal Impairment Study
Renal Insufficiency
Primary: Area Under the Curve From Time Zero to 48 Hours[AUC (0 - 48)] — 1294; 1399; 2024; 2860 Nanogram*hour/milliliter (ng*h/mL)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=31 Mild, Moderate and Severe Renal Impairment Study
Gout
Primary: Maximum Observed Plasma Concentration (Cmax) — 25.6; 29.0; 38.2; 16.7 ng/mL
N/A N=15,724 Intensive Monitoring of Renal Function
Intensive Monitoring of Renal Function · Acute Kidney Injury
Primary: Detection of Acute Kidney Injury (AKI) — 1.22; 1.22; 1.11; 1.11 Odds Ratio
Phase 3 N=91 An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)
Diabetes Mellitus, Type 2 · Chronic Renal Insufficiency
Primary: Safety and Tolerability of Sitagliptin After 12 Weeks of Treatment — 41; 16; 8; 1 Participants
Phase 2 N=54 Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients
Secondary Hyperparathyroidism · Chronic Renal Insufficiency
Primary: Reduction in Mean iPTH of ≥ 30% During the Efficacy Assessment Phase — 15; 5 Participants — p=0.006
Phase 2 N=32 Exercise Intolerance in Renal Failure
Kidney Failure, Chronic
Primary: Change in Resting Muscle Sympathetic Nerve Activity (MSNA) — -7.5; 3.2 bursts/minute
Phase 1 N=23 A Renal Impairment Study for PF-04965842
Renal Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) for PF-04965842 — 1174; 1626; 1164 nanogram per milliliter (ng/mL)
Phase 1 N=24 A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02
Impaired Renal Function
Primary: Pharmacokinetic Parameters- Plasma AUC0-24 — 16877.94; 32787.41; 64895.29; 15506.68 ng*h/mL
Phase 4 N=511 A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment
Kidney Diseases · Coronary Artery Disease
Primary: Number of Subject With Serious Treatment Emergent Adverse Events (TEAE) — 0; 0 Subjects
Phase 2 N=24 Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
ESRD
Primary: Change in Leucine Disposal Rate (LDR) — -0.011; 0.005; 0.001 mg/kg/min — p=0.37
Phase 1 N=30 Renal Impairment Study of PF-06700841
Healthy Volunteer · Renal Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-06700841 Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants…
Phase 1 N=27 Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.
Renal Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-07321332 — 1600; 2077; 2210; 2369 Nanogram per milliliter
Phase 4 N=60 Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
Atrial Fibrillation
Primary: Pre-dose Concentration of the Analyte in Plasma at Steady State Immediately Before Administration of the Next Dose — 155 ng/mL
Phase 1 N=29 Lorlatinib Renal Impairment Study
Renal Impairment
Primary: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Lorlatinib — 8329; 8683; 9890; 11760 ng*hr/mL
Phase 1 N=30 Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment
Renal Impairment · Healthy
Primary: Cmax — 545.4; 593.2; 475.9 ng/mL
Phase 4 N=213 Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)
Chronic Kidney Disease · Renal Insufficiency
Primary: Capture of Post-marketing Safety Information in Patients With Moderate Renal Insufficiency Undergoing Routine Contrast-enhanced MRI With Administration of OMNISCAN in…
Phase 3 N=182 Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia
Anemia
Primary: Patients With an Increase in Hemoglobin >= 1gm/dL. — 35; 23 participants
Phase 1 N=29 A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
Pneumonia
Primary: Maximum Observed Plasma Concentration (Cmax) of CP-70429 Following CP-70,429 Intravenous Dose — 17700; 22070; 28940; 10340 nanogram per milliliter (ng/mL)
Phase 4 N=114 Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency
Type 2 Diabetes · Renal Insufficiency
Primary: Average Blood Glucose Over 6 Days — 174; 174.5 milligrams per deciliter — p=.958
Phase 1 N=18 A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)
Renal Impairment
Primary: Area Under the Concentration Versus Time Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of MK-8527 in Plasma — 769; 1160; 1430 nM·hr
Phase 1 N=24 Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function
Renal Impairment
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] — 268; 370; 396; 615 nanogram*hour/milliliter (ng*hr/mL)
Phase 1 N=18 A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007)
Moderate Renal Impairment
Primary: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of MK-0616 — 453; 369 hour*nmol/Liter
Phase 4 N=57 Kidney Damage in Patients With Moderate Fall in eGFR
Coronary Artery Stenosis
Primary: Impact on the Trajectory of Serum and Urinary Neutrophil Gelatinase-associated Lipocalin (NGAL) Following Administration — -27.76; -11.11; -11.84; -8.23 ng/mL
Phase 3 N=100 Omega 3 Fatty Acids in Patients With Chronic Renal Disease
Renal Insufficiency, Chronic
Primary: Number of Participants With a Urine Albumin Excretion Decrease of 20% or More — 19; 13 Participants — p=0.257
Phase 1 N=32 Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment
Hepatitis C
Primary: AUC0-∞ — 76500; 86900; 136000; 129000 ng*h/mL
N/A N=9 Effects of Obesity Surgery on Renal Function
Impaired Renal Function
Primary: Changes in Glomerular Renal Function After Weight Loss Surgery as Measured by 51Cr-EDTA Clearance — 0 Participants
Phase 1 N=49 A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)
Infectious Disease
Primary: Part 1: Area Under the Plasma Concentration-time Curve From Dosing to Infinity (AUC0-inf) of MK-7655 in Combination With PRIMAXIN® — 73.5; 45.0; 115; 52.3 µM*hr
Phase 3 N=294 RenalGuard System and Contrast Media
Chronic Kidney Disease
Primary: Number of Participants With Contrast-induced Acute Kidney Injury — 146; 146 participants
Phase 4 N=357 Primovist / Eovist in Renally Impaired Patients
Contrast Media
Primary: Number of Participants With Moderate to Severe Renal Impairment, Who Develop NSF (Nephrogenic Systemic Fibrosis), Based on Diagnostically Specific Clinical and…
N/A N=168 Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Fibrosis · Kidney Failure · Renal Insufficiency
Primary: Number of Participants Who Developed Nephrogenic Systemic Fibrosis (NSF), Based on Diagnostically Specific Clinical and Histopathological Information-cohort Analysis and…